U.S. Markets close in 2 hrs 42 mins

GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher

Zacks Equity Research

GlycoMimetics, Inc. GLYC was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 26.2% in the past one-month time frame.

The company has seen three positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for GlycoMimetics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

GlycoMimetics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

GlycoMimetics, Inc. Price

GlycoMimetics, Inc. Price | GlycoMimetics, Inc. Quote

A better-ranked stock in the Medical sector is MEI Pharma, Inc. MEIP, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is GLYC going up? Or down? Predict to see what others think: Up or Down.

Can Hackers Put Money INTO Your Portfolio?

Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.

Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.

Download the new report now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
MEI Pharma, Inc. (MEIP) : Free Stock Analysis Report
 
GlycoMimetics, Inc. (GLYC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research